Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Manage cookie preferences ...

Following news of U.S. President Donald Trump’s 10% across-the-board tariffs on Australian exports to the U.S., Australia’s ...

Amygdala Neurosciences Inc. has selected ANS-858 as its lead clinical candidate for substance use disorders, that includes ...

Biomedical research seems like it should be the ultimate bipartisan issue. But under the Trump administration, unless and ...

President Donald Trump’s executive order on global tariffs have pushed downward the stocks of biopharma and med-tech ...

The Trump administration’s declaration of a new round of tariffs did not sit well with trade associations, but the impact of those tariffs may vary somewhat by company. Analysts said the lack of ...

The U.S. FDA cleared Artrya Ltd.’s Salix Coronary Anatomy software that analyzes coronary computed tomography angiogram scans ...

Tenvie Therapeutics Inc. has divulged NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of glaucoma, spinal cord injury, multiple sclerosis, Niemann-Pick ...

Scientists at Mayo Foundation for Medical Education and Research (MFMER) and Sanford Burnham Prebys Medical Discovery Institute have described G-protein coupled bile acid receptor 1 (GPBAR1; TGR5; ...

Calla Lily Clinical Care Ltd. secured £1 million (US$1.3 million) in funding from the National Institute for Health and Care Research to begin clinical trials of Callavid, a drug delivery technology ...

The U.S. FDA’s accelerated approval of Vanrafia (atrasentan) from Novartis AG for primary immunoglobulin A nephropathy (IgAN) is the company’s second approval for the indication in the past year and a ...

Regenerative heart therapy, integrating biocompatible materials with nucleic acids, proteins and live cells, offers a promising personalized approach to treating cardiac ischemic reperfusion injury ...